Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
This CDC report provides updated data related to HIV prevalence among people who inject drugs, documenting findings that underscore the need for low-barrier access to comprehensive and integrated needs-based syringe service programs for necessary prevention and
This PowerPoint slide deck reviews the foundations of harm reduction philosophy and practice, summarizes drug user health issues and trends, and aims to increase cultural competence and humility when working with people who use drugs.
This tool aims to assist HIV primary care teams that work in a range of clinical settings to develop and provide enhanced integration of behavioral health (BH) services.
This discussion guide is intended to elicit a comprehensive and concrete conversation about language, stigma, and discrimination as a means of strengthening care systems and ensuring that people who seek care for HIV and/or substance use disorders, including opioid use disorder, are treated with
This month’s Connecting Care episode continues the conversation about barriers to methadone treatment for patients, stigma, and what we can learn from other countries to advance policy and practice for methadone in the US.
This month’s Connecting Care episode discusses the challenges associated with entering and staying in methadone treatment programs and opportunities to improve treatment experiences for all.
In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
Pagination
- Previous page ‹‹
- Page 2
- Next page ››